1. Introduction
The hematopoietic system comprises all blood-forming tissues, including the bone marrow, lymph nodes, spleen, liver and thymus, as well as a range of circulating specialized blood cell types, including erythrocytes, megakaryocytes and adaptive and innate immune cells. Hematopoietic stem cells (HSCs) are essential for replenishing blood cells, a process known as hematopoiesis. Capable of both self-renewal and multipotent differentiation, HSCs are primarily found in the bone marrow in adults, with a small number also circulating in the peripheral blood. Umbilical cord blood is also a rich source. The term hematopoietic stem and progenitor cells (HSPCs) includes both HSCs and progenitor cells which have become committed to differentiating into certain lineages and lack self-renewal ability [1]. CD34 is expressed on most HSPCs and the terms HSC, HSPC and CD34+ cells tend to be used interchangeably, despite being distinct.
The ability of HSCs to reconstitute the entire blood system enables hematopoietic cell transplant (HCT), a procedure whereby stem cells are infused into patients with various cancers or certain non-malignant conditions following a short course of chemotherapy or radiotherapy [2]. Most HCTs are carried out to cure an underlying malignancy or hematologic disorder. HSCs can be obtained from the recipient (autologous) or from donors (allogeneic) from bone marrow, peripheral blood or cord blood. Both autologous and allogeneic HCT are performed to allow the recipient to recover from a high-dose chemotherapeutic conditioning regimen, with or without radiotherapy. In addition, with allogeneic HCT, the immune cells in the graft may provide a graft-versus-tumor response which may be beneficial for certain patients. While, overall, the number of autologous transplants exceeds that of allogeneic transplants [3], the decision between autologous and allogeneic transplantation is guided by which approach has demonstrated superior efficacy in clinical studies [2]. Worldwide, more than 50,000 HCT procedures are performed annually with most performed for hematologic malignancies [4]. Non-malignant disorders suitable for HCT include autoimmune diseases such as multiple sclerosis, systemic sclerosis and certain cases of Crohn’s disease and systemic lupus erythematosus among others, as well as inherited diseases including severe combined immunodeficiency (SCID), thalassemia and sickle cell disease (SCD) [4].
While allogeneic HCT has been used for decades as a curative treatment for certain non-malignant conditions, significant challenges exist include sourcing of suitable donors as well as risks of graft-versus-host disease, graft failure and treatment-related mortality [5]. Recent discoveries and developments in the field of gene editing have meant that allogeneic HSCs can be modified to improve functionality [6]. However, to date, gene therapy/editing has been explored more extensively for autologous HCT towards curative treatment for several inherited blood disorders (Figure 1) [7]. Gene therapy by gene addition, involving the semi-random integration of one or more copies of a therapeutic gene into the HSC genome, has long been studied for inherited disorders [8]. Retroviruses are typically used as vectors due to their ability to stably transduce HSCs. Serious adverse events during early studies led to the development of safer gamma-retroviral and lentiviral vectors but the risk of insertional mutagenesis remains [8]. Progress in gene-editing technologies has stimulated studies exploring the ability of these tools to correct mutations in HSCs. Here we present a comprehensive overview of clinical trials for hemoglobinopathies and immunodeficiencies that utilize gene-edited autologous HSCs. The development and approval of CASGEVY is used as a central case study to illustrate bench-to-bedside translation.
2. Gene-Editing Tools
In recent years, remarkable progress in genetic engineering, and gene editing in particular, has been achieved. The following is a brief overview of the gene-editing tools used in the clinical trials covered herein.
2.1. Zinc-Finger Nucleases
Zinc-finger nucleases (ZFNs) are engineered proteins consisting of a DNA-binding domain fused to the cleavage domain of the FokI nuclease and were the first programmable nucleases developed to enable targeted genome editing in mammalian cells [9]. The DNA-binding domain comprises an array of zinc-finger motifs, each of which typically recognizes a specific 3-nucleotide sequence triplet of DNA bases. Two ZFN monomers bind to adjacent DNA sequences to induce a double-stranded break (DSB), following which a DNA repair process called non-homologous end joining (NHEJ) is initiated by the cell. This process is error prone, often resulting in insertions or deletions of nucleotides (indels), which may lead to a reduction in gene expression, thus achieving functional gene knockout. In a related process, insertion of a DNA sequence, or knockin, can be achieved. For this, the desired DNA segment is co-delivered with the ZFN and can be inserted into the cut site in a process called homology-directed repair (HDR) (Figure 1) [7]. However, ZFN-mediated gene editing has been limited by the requirement for extensive protein engineering expertise as well as off-target cleavage events and cytotoxicity.
2.2. CRISPR-Cas9 and CRISPR-Cas12 Nucleases
First discovered in bacteria as a defense mechanism against viral infection, clustered regularly interspaced short palindromic repeats (CRISPRs)-associated (Cas) proteins are endonucleases that catalyze site-specific cleavage of double-stranded DNA [9]. Several Cas proteins have now been identified in various bacterial systems and Cas9, followed by Cas12a, are the most widely used as gene-editing tools. These proteins combine with a short guide RNA (gRNA) molecule to form a ribonucleoprotein (RNP) (Figure 1). The gRNAs are complementary to the target DNA sequence which is known as the protospacer. For gene editing, the RNP enters the nucleus and the Cas9 protein scans the DNA for a short recognition sequence called protospacer adjacent motif (PAM) which must be immediately downstream of the target DNA sequence. If the adjacent DNA sequence matches the gRNA, Cas9 creates a DSB in the DNA at that site. Gene knockout or knockin can be achieved via NHEJ or HDR respectively. Differences between Cas9 and Cas12 include the employment of different PAM sites and the production of blunt cuts by Cas9 compared with staggered cuts by Cas12a, the latter of which are beneficial for gene insertion. However, limitations of CRISPR-Cas systems include unintended and unpredictable genome alterations including off-target indels, large-scale deletions at on-target sites, chromosome losses or truncations and potential genotoxicity of DSBs [10,11].
2.3. Base Editors
To address the limitations associated with CRISPR-Cas systems, base and prime editors have been developed to enable precise single or multiple base substitutions in DNA without introducing DSBs. Base editors (BEs) are fusion proteins comprising a modified Cas9 nickase (nCas9) fused to a nucleotide deaminase enzyme [12]. In these systems, the gRNA guides the complex to the target site in the genome, the Cas9 nickase induces a single strand break and the specific deaminases catalyze deamination of the single-stranded DNA. While cytosine base editors (CBEs) and adenine base editors (ABEs) were first developed, mediating the conversion of cytosine (C)-to-thymine (T) and adenine (A)-to-guanine (G) respectively, a number of BEs have now been designed that can achieve a range of base edits [12]. While avoiding the issue of DSBs seen with CRISPR-Cas systems, off-target base editing can still occur, and this is believed to be primarily caused by the deaminases.
2.4. Glycosylase Base Editors
To further improve gene-editing efficiency and specificity, deaminase-free BEs have been developed which contain a glycosylase fused to a nCas9 to directly perform base editing without deamination [13]. It is suggested that these systems may have advantages over deaminase-based BEs due to their smaller size, simpler cellular mechanism and wider base-editing types; however, off-target edits persist [14].
2.5. Prime Editors
Prime-editing systems were developed to improve precision and flexibility of gene editing. These systems comprise nCas9 with the nuclease domain deactivated, an engineered reverse transcriptase (RT) domain, and a prime-editing guide RNA (pegRNA) that incorporates a reverse transcription template (RTT) and an additional primer binding sequence [10]. The nCas9 generates a single strand break at the target site in the genomic DNA and the RT reads the RNA template built into the pegRNA to synthesize a complementary DNA strand. This newly made DNA fragment containing the desired edit is then incorporated into the genome during DNA repair. Low editing efficiency and off-target edits remain a challenge with these systems [10].
3. Clinical Trial Identification and Data Sources
We identified 44 interventional clinical trials investigating gene-edited autologous stem cell therapeutic candidates and these are summarized in Table 1 and Table 2. The trials were identified primarily through the Clinical Trials Register curated by CRISPR Medicine News (CMN) (https://crisprmedicinenews.com/trialdb/, URL last accessed on 31 December 2025). This register contains publicly disclosed gene-editing clinical programs. To maximize coverage, CMN’s resource was complemented by systematic searches of major international clinical trial registries, including ClinicalTrials.gov (National Institutes of Health [NIH], Bethesda, MD, USA), the Chinese Clinical Trial Registry (ChiCTR), the EU Clinical Trials Register, the ISRCTN registry (United Kingdom), and the Australia and New Zealand Clinical Trials Registry (ANZCTR).
We performed searches at the aforementioned international registries using various combinations of keywords related to gene-editing technologies (including “gene editing”, “CRISPR”, “Cas9”, “Cas12”, “base editing”, “prime editing”, “zinc finger nuclease”, “TALEN”, and “meganuclease”) together with terms describing autologous stem or progenitor cell therapies (including “autologous”, “stem cell”, “hematopoietic stem cell”, “HSPC”, “CD34+”, and “genetically modified”).
Identified trials were manually curated to confirm the use of genome-editing technologies, and that any candidate therapy under investigation was patient-derived and of stem or progenitor cell source. The final search was completed on 31 December 2025. While we cannot rule out the possibility that additional studies exist that are not publicly registered or disclosed, we believe that the trials presented herein provide a comprehensive and representative overview of clinical-stage gene-edited autologous stem cell therapies worldwide at the time of analysis.
4. Broad Overview of All Clinical Trials Uncovered in This Review
The 44 identified trials are summarized in Table 2 and reflect a rapidly growing and increasingly diversified clinical pipeline. The vast majority of studies focus on hemoglobinopathies (n = 37), inherited disorders of hemoglobin synthesis, more specifically sickle cell disease (SCD) and β-thalassemia, which together represent the most clinically advanced applications of autologous stem cell editing. A smaller subset of trials target primary immunodeficiencies (n = 4), including X-linked severe combined immunodeficiency (X-SCID), X-linked chronic granulomatous disease (X-CGD), autosomal recessive chronic granulomatous disease, and CD40L-linked Hyper-IgM syndrome. The remaining trials (n = 3) explore edited autologous stem cells in other disease contexts, including single trials in HIV-1 infection, the inherited metabolic disorder pyruvate kinase deficiency (PKD) and limb–girdle muscular dystrophy (LGMD), the latter involving gene-edited muscle satellite stem cells rather than hematopoietic progenitors. Collectively, these 44 trials illustrate the dominance of hematological indications in the field and the emergence of gene-edited autologous stem cell therapies in other disease areas.
Most of the identified trials are in the early phase, with Phase 1 or combined Phase 1/2 studies comprising the majority (n = 34), reflecting an overall landscape that is still maturing clinically. Despite the early-phase dominance referred to above, a considerable number of trials (n = 6) have progressed to late-stage evaluation, including several Phase 3 trials of CRISPR-Cas9-edited CD34+ HSPCs for sickle cell disease (SCD) and β-thalassemia (BT). Importantly, these clinical efforts have culminated in the first regulatory approval of a gene-edited autologous stem cell therapy, exagamglogene autotemcel (exa-cel; marketed as CASGEVY). Exa-cel is a CRISPR-Cas9-edited autologous stem cell therapy developed for the treatment of SCD and transfusion-dependent β-thalassemia (TDT) through targeting of the BCL11A erythroid enhancer, and it remains the only gene-edited therapy approved to date.
Although recruitment occurs across multiple countries, most trials are sponsored by organizations based in the United States or China. A small number of trials are led by sponsors based in other regions, most notably Europe (e.g., NCT05588401). Across the 44 trials, CRISPR-based technologies (including those based on Cas9, Cas12a, and Cas12b) dominate (n = 28), while base editing (n = 12), ZFNs (n = 3) and prime editing (n = 1) are also represented, highlighting the increasing diversification of gene-editing platforms entering the clinic.
While the approaches described above rely primarily on ex vivo editing of autologous hematopoietic stem and progenitor cells followed by myeloablative conditioning, several emerging strategies may influence the next generation of gene-editing therapies. These include the development of chemotherapy-free conditioning approaches, in vivo genome-editing strategies designed to target hematopoietic stem cells directly within the body, and new delivery platforms such as lipid nanoparticles (LNPs) and virus-like particles (VLPs) [32,33,34]. These developments are currently advancing largely within preclinical programs but have the potential to improve the safety, accessibility, and scalability of gene-editing therapies and may influence the design of future clinical trials.
5. Gene-Editing Approaches to Treat Hemoglobinopathies
As outlined above, hemoglobinopathies account for the largest proportion of current clinical trials of gene-edited autologous stem cell therapies. SCD and TDT arise from mutations in the hemoglobin β-subunit gene, HBB, which encodes a critical component of the major oxygen-carrier adult hemoglobin A (HbA). Both diseases belong to the broader group of inherited hemoglobin disorders collectively termed hemoglobinopathies. SCD and TDT are among the most common monogenic diseases worldwide, with approximately 60,000 and 300,000 new diagnoses reported annually, respectively [19].
6. Etiology of Hemoglobinopathies and Current Treatments
TDT can arise through more than 200 known mutations in HBB, resulting in severely reduced or absent β-globin synthesis and an imbalance between the α-like and β-like globin chains that make up HbA [35]. This leads to insufficient mature, functional adult hemoglobin and ineffective erythropoiesis, chronic anemia, dysregulated iron metabolism and organ toxicity, all of which contribute to poorer quality of life, reduced life expectancy and increased morbidity [35,36,37,38,39,40].
SCD arises through a single point mutation in HBB that substitutes glutamic acid with valine at amino acid position 6. This results in the production of sickle hemoglobin (HbS) which polymerizes to form long, rigid chains when oxygen levels are low. This causes red blood cells to become crescent- or sickle-shaped and compromises their ability to pass through small blood vessels. SCD manifests as a complicated disease involving red blood cell deformation, hemolysis, anemia, painful vaso-occulative episodes caused by the inability of sickled cells to pass through small blood vessels, irreversible organ damage and reduced life expectancy [19,41].
Standard treatment approaches to SCD and TDT are non-curative, including blood transfusions, pain management and symptom relief. Additionally, iron chelation therapy is used to manage iron overload in TDT patients receiving blood transfusions and the anti-cancer agent hydroxyurea is used in the treatment of SCD [42,43,44]. Hydroxyurea was the first therapy to receive FDA approval for SCD (in 1997). It promotes the production of fetal hemoglobin and is widely used in the treatment of SCD today, although its mechanism of action remains poorly defined [43,44].
Recently approved therapies including luspatercept (a recombinant protein-based therapy that promotes erythroid maturation) and crizanlizumab (a monoclonal antibody that improves the flow of sickled red blood cells through blood vessels) have reduced some symptoms of TDT and SCD, respectively, but neither addresses the root cause of disease nor fully ameliorates all disease manifestations [45,46]. Allogeneic bone marrow transplantation has curative potential for TDT and SCD, but the severe shortage of suitable donors and life-threatening complications associated with transplantation renders this approach unrealistic for the vast majority of patients [36,47,48].
Two gene-addition therapies have gained regulatory approval for hemoglobinopathies. These include Zynteglo® (betibeglogene autotemcel), a lentiviral vector-based β-globin gene-addition therapy approved for TDT, and Lyfgenia® (lovotibeglogene autotemcel), a similar lentiviral gene-addition therapy approved for the treatment of SCD in the United States, both of which rely on lentiviral gene addition rather than targeted genome modification [49,50,51].
7. Breakthrough Discoveries in Globin Gene Regulation That Enabled New Therapeutic Strategies for Hemoglobinopathies
A major advance in the treatment of hemoglobinopathies arose from clinical observations that persistence of fetal hemoglobin (HbF) expression into adulthood markedly ameliorates disease severity in both SCD and TDT [41,52,53,54,55,56,57,58]. Under normal physiological conditions, HbF expression is developmentally silenced shortly after birth through a tightly regulated transcriptional switch from γ-globin to β-globin production, such that adult red blood cells contain predominantly HbA [59], as shown in Figure 2.
Individuals with hereditary persistence of fetal hemoglobin (HPFH) exhibit reduced clinical manifestations of SCD or TDT despite carrying pathogenic HBB mutations, demonstrating that elevated HbF can functionally compensate for defective adult β-globin [52]. These observations established HbF reactivation as a compelling therapeutic strategy that could treat both SCD and TDT through modulation of globin gene regulation rather than direct correction of disease-causing HBB mutations. Consistent with this rationale, the majority of gene-editing strategies currently in clinical development for hemoglobinopathies center on reactivation of fetal hemoglobin through modification of globin regulatory elements, rather than direct correction of disease-causing HBB mutations (see Table 1 and Table 2).
Decades of molecular and genetic studies (detailed in [59]) carried out to understand the regulation of fetal hemoglobin expression culminated in the identification of three genomic loci harboring common variants associated with inter-individual differences in HbF levels [60,61,62,63]. Among these, the B-cell lymphoma/leukemia 11A (BCL11A) gene on chromosome 2 emerged as a central, developmentally regulated repressor of γ-globin expression [64,65]. BCL11A encodes a zinc-finger transcription factor, and functional studies demonstrated that genetic inactivation or knockdown of BCL11A robustly induces HbF production in adult erythroid cells without significantly impairing erythroid differentiation, establishing BCL11A as a target for therapeutic HbF reactivation [65,66,67,68].
Despite its strong therapeutic rationale, direct targeting of BCL11A initially posed a major translational challenge, as loss of BCL11A function outside the erythroid lineage is incompatible with normal hematopoiesis, particularly B-lymphocyte development, thereby limiting the feasibility of global BCL11A inhibition [62]. Subsequent mechanistic studies identified an erythroid-specific enhancer element controlling BCL11A expression, revealing a strategy by which BCL11A activity could be selectively attenuated in erythroid cells [69]. This discovery provided the foundation for current therapeutic approaches that target the erythroid-specific BCL11A enhancer to induce fetal hemoglobin while preserving essential BCL11A functions in other hematopoietic lineages (see Table 1).
The emergence of genome-editing technologies enabled direct, loss-of-function interrogation of regulatory DNA elements controlling the fetal-to-adult globin switch, exemplified by targeted disruption of the erythroid-specific BCL11A enhancer [70,71]. In the case of CASGEVY, CRISPR-Cas9-mediated disruption of the erythroid-specific enhancer of BCL11A selectively reduces BCL11A expression in erythroid cells, resulting in durable fetal hemoglobin induction with an HPFH-like phenotype that enabled the first approved gene-edited autologous stem cell therapy (see Scheme 1). In parallel, alternative HbF induction strategies are advancing clinically that more directly mimic naturally occurring HPFH mutations, including editing of the γ-globin gene (i.e., HBG1/HBG2) promoters to disrupt repressor binding sites (e.g., for BCL11A and others) to maintain HbF expression into adulthood (see Table 1 and Table 2).
8. Clinical Data Supporting Regulatory Approval of CASGEVY
Phase 3 clinical data for CASGEVY were published in 2024 from pivotal clinical trials in SCD and TDT [20,50,72]. In both trials, patients received a single infusion of CASGEVY following myeloablative busulfan conditioning, which was required to facilitate durable engraftment of edited cells.
In SCD, efficacy was evaluated in the single-group, open-label CLIMB SCD-121 study (NCT03745287). This study enrolled 44 adolescents and adults (12 to 35 years old) with SCD who had suffered at least two severe VOCs in each of the two years before screening. The primary and key secondary endpoints were freedom from severe VOCs for a continuous period of at least 12 months and freedom from hospitalization for severe VOCs for 12 consecutive months. Of the patients eligible for analysis, 97% and 100% met the primary and key secondary endpoints, respectively. Patients exhibited early and sustained increases in total hemoglobin and HbF levels, and improvements were seen in all markers of hemolysis evaluated [72].
In TDT, Phase 3 data were obtained from the CLIMB THAL-111 study (NCT03655678), which enrolled 52 adolescents and adults (12 to 35 years old) with TDT who had a high burden of red blood cell transfusions and impaired life quality. The primary endpoint was transfusion independence for at least 12 consecutive months while maintaining adequate hemoglobin levels. Of all enrolled patients, 97% achieved transfusion independence, with hemoglobin levels maintained predominantly through durable HbF induction [20].
In both trials, durable engraftment of edited CD34+ cells and sustained HbF expression were observed over reported follow-up periods extending beyond one year. The safety profile of CASGEVY was consistent with that expected following myeloablative conditioning and autologous hematopoietic cell transplantation, with no serious adverse events attributed to gene editing and no evidence of clonal dominance or malignant transformation during follow-up [20,50,72]. Together, these Phase 3 studies represent the most advanced clinical data reported to date for a gene-editing therapeutic.
9. Global Regulatory Approval of CASGEVY
Exagamglogene autotemcel (Exa-cel; marketed as CASGEVY), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, was first approved by the UK Medicines and Healthcare products Regulatory Agency in November 2023 for the treatment of both sickle cell disease and transfusion-dependent β-thalassemia. This was followed by breakthrough approval from the US Food and Drug Administration in December 2023 for sickle cell disease and subsequently in January 2024 for transfusion-dependent β-thalassemia. Conditional approval was granted by the European Commission in February 2024 for both indications. Beyond the UK, United States, and European Union, CASGEVY has received regulatory approval in several additional jurisdictions, including Canada, Switzerland, Saudi Arabia, and Bahrain in 2024, with further approvals following in the United Arab Emirates and Qatar in 2025.
10. Gene-Editing Approaches to Treat Immunodeficiencies
In addition to hemoglobinopathies, a growing number of clinical trials are evaluating gene-edited autologous hematopoietic stem and progenitor cell (HSPC) therapies for the treatment of inherited immunodeficiencies (n = 4; Table 2). These studies focus on monogenic disorders caused by loss-of-function mutations in genes that are essential for immune cell development or effector function and predominantly employ direct gene correction or inactivation strategies (see targeting rationales in Table 1).
Current clinical programs include three Phase 1/2 trials sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), targeting distinct primary immunodeficiencies through base editing of autologous HSPCs. These trials, which are either recruiting or enrolling by invitation, involve correction of IL2RG mutations in X-linked severe combined immunodeficiency (X-SCID; NCT06851767), correction of CYBB mutations in X-linked chronic granulomatous disease (X-CGD; NCT06325709), and correction of CD40LG mutations in CD40L-associated Hyper-IgM syndrome (NCT06959771) [73,74]. An ongoing Phase 1/2 trial sponsored by Prime Medicine is evaluating PM359, a prime-edited autologous HSPC therapy designed to correct pathogenic mutations in NCF1 for the treatment of autosomal recessive p47^phox-deficient chronic granulomatous disease (NCT06559176). Initial clinical data published in late 2025 demonstrated rapid hematopoietic engraftment, durable restoration of NADPH oxidase activity, and early clinical benefit without genome-editing-related safety concerns, providing the first clinical validation of prime editing in autologous HSPCs [31].
11. Clinical-Stage Gene-Editing Approaches Beyond Hematologic Indications
A small number of additional trials extend gene-editing approaches beyond classical hemoglobinopathies and primary immunodeficiencies (n = 3; Table 2). A Phase 1 trial in HIV-1 infection, sponsored by Sangamo Therapeutics, is evaluating ZFN-mediated disruption of the host CCR5 co-receptor in autologous CD34+ HSPCs to reduce viral susceptibility, representing a host-directed therapeutic strategy rather than correction of a disease-causing mutation (NCT02500849) [75]. In addition, a recruiting Phase I study in pyruvate kinase deficiency (PKD), sponsored by Shanghai Children’s Medical Center, is assessing CRISPR/adeno-associated virus (AAV6)-mediated targeted insertion of a codon-optimized PKLR cDNA into autologous CD34+ HSPCs to restore pyruvate kinase activity and erythroid metabolic function (ChiCTR2300073795). In contrast to the hematopoietic focus of most of the trials discussed herein, a single trial sponsored by Simone Spuler, MD, at Charite University in Berlin applies CRISPR-Cas9 editing to an undisclosed genomic target in autologous muscle satellite stem cells for LGMD (NCT05588401) [76], highlighting the application of genome-editing technologies into non-hematopoietic stem cell compartments.
12. Conclusions
Advances in understanding of disease genetics and the ongoing development of genome-editing tools are informing strategies for novel approaches to treating blood disorders. The approval of CASGEVY represents a pivotal milestone, validating the clinical feasibility of personalized, gene-edited cell therapies. However, the high cost and complex manufacturing associated with such therapies present important challenges for global accessibility, prompting initiatives such as the Global Gene Therapy Initiative aimed at improving equitable access to these treatments worldwide [77]. Many other approaches have moved into the clinic and results will inform future strategies. Technical challenges with gene-editing tools continue to be discovered and addressed, driving iterative improvements in editing precision and safety that will be critical for the broader and more durable application of these therapies. Emerging computational approaches and advances in conditioning strategies, in vivo genome-editing methods, and next-generation delivery platforms such as LNPs and VLPs may further support the evolution of gene-editing therapies and shape the design of future clinical trials.